BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer

BioNTech delivered a compelling piece of evidence Monday supporting the development of its CTLA-4 antibody gotistobart in lung cancer. Previously treated lung cancer patients who received the CTLA-4 antibody lived for 8.5 months longer than ...